ADMA Biologics, Inc.
ADMA
$16.18
-$0.40-2.41%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 3.68% | 10.03% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 3.68% | 10.03% | |||
| Cost of Revenue | -14.08% | 7.01% | |||
| Gross Profit | 17.44% | 12.49% | |||
| SG&A Expenses | 6.90% | -1.36% | |||
| Depreciation & Amortization | 34.21% | 18.75% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.17% | 5.08% | |||
| Operating Income | 23.01% | 19.19% | |||
| Income Before Tax | 29.63% | 18.50% | |||
| Income Tax Expenses | 10.18% | 88.62% | |||
| Earnings from Continuing Operations | 35.55% | 6.46% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 35.55% | 6.46% | |||
| EBIT | 23.01% | 19.19% | |||
| EBITDA | 22.18% | 18.23% | |||
| EPS Basic | 35.89% | 7.76% | |||
| Normalized Basic EPS | 24.27% | 21.91% | |||
| EPS Diluted | 33.27% | 7.14% | |||
| Normalized Diluted EPS | 24.43% | 22.37% | |||
| Average Basic Shares Outstanding | -0.26% | -1.20% | |||
| Average Diluted Shares Outstanding | -0.33% | -1.59% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||